Retatrutide appears to be a new treatment in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, Cagrillintide USA manufacturer and ultimately contributes to